The Medical Letter on Drugs and Therapeutics
Baricitinib (Olumiant) for Rheumatoid Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the Janus kinase (JAK) inhibitor baricitinib (Olumiant – Lilly) for oral treatment of adults with moderately to severely active rheumatoid arthritis (RA) that has not responded adequately to one or more tumor necrosis factor (TNF) inhibitors. Baricitinib is the second JAK inhibitor to be approved for treatment of RA; tofacitinib (Xeljanz, Xeljanz XR) was the first.1

STANDARD TREATMENT — For initial treatment of RA, a disease-modifying antirheumatic drug (DMARD) is recommended to achieve clinical remission and prevent irreversible damage to joints; a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid is usually added for symptom control. Methotrexate is generally the DMARD of choice; hydroxychloroquine and sulfasalazine are safer alternatives that may be appropriate in mild cases. Guidelines generally recommend use of a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Baricitinib (Olumiant) for Rheumatoid Arthritis
Article code: 1551c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian